
    
      This is an extension of the phase II, three-arm, parallel design, dose-ranging,
      placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1)
      of two (2) dose levels of ProellexÂ® was administered once-daily for four (4) months.
    
  